Emergent Signs Five-year Deal Backing J&J COVID-19 Vaccine
Emergent BioSolutions Inc. said on Monday it had signed a five-year pact to make the drug substance used in Johnson & Johnson’s COVID-19 vaccine candidate, adding to a series of contracts likely to put it at the heart of future global vaccine production.
Under the deal, starting next year Emergent will provide large-scale manufacturing services to produce the drug substance over five years, with the first two years valued at about $480 million.
The news follows a $135 million deal struck by the two companies in April, to use Emergent’s manufacturing facilities to help make more than 1 billion doses of the vaccine J&J is testing to stop the coronavirus.
Emergent has also signed similar deals to expand the manufacturing capacity of COVID-19 vaccines under development by AstraZeneca Plc, Novavax Inc and Vaxart Inc.
The company last month also agreed a $628 million contract with the U.S. government, which is looking to secure manufacturing capacity for a potential COVID-19 vaccine under its “Operation Warp Speed” program.
Neha writes articles on sectors including medicine, food, materials, and science & technology. A qualified statistician, she has the ability to observe and analyze the trends in global markets and write compelling articles that help CXOs in decision making. She is a bookworm and loves to read fiction, lifestyle, science and technology. Neha comes with 6 years of experience in content writing and editing that involves blog writing, preparation of study materials and OERs.